The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword
<p dir="ltr">Chronic kidney disease (CKD) is an increasing global health burden. Current treatments for CKD include therapeutics to target factors that contribute to CKD progression, including renin–angiotensin–aldosterone system inhibitors, and drugs to control blood pressure and pr...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513515825397760 |
|---|---|
| author | Eman Wehedy (13275305) |
| author2 | Ibrahim F. Shatat (14150601) Souhaila Al Khodor (89983) |
| author2_role | author author |
| author_facet | Eman Wehedy (13275305) Ibrahim F. Shatat (14150601) Souhaila Al Khodor (89983) |
| author_role | author |
| dc.creator.none.fl_str_mv | Eman Wehedy (13275305) Ibrahim F. Shatat (14150601) Souhaila Al Khodor (89983) |
| dc.date.none.fl_str_mv | 2022-01-17T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3389/fmed.2021.790783 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/The_Human_Microbiome_in_Chronic_Kidney_Disease_A_Double-Edged_Sword/25663881 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences chronic kidney disease gut microbiota urinary microbiome dysbiosis uremic toxins renoprotective diet therapy |
| dc.title.none.fl_str_mv | The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Chronic kidney disease (CKD) is an increasing global health burden. Current treatments for CKD include therapeutics to target factors that contribute to CKD progression, including renin–angiotensin–aldosterone system inhibitors, and drugs to control blood pressure and proteinuria control. Recently, associations between chronic disease processes and the human microbiota and its metabolites have been demonstrated. Dysbiosis—a change in the microbial diversity—has been observed in patients with CKD. The relationship between CKD and dysbiosis is bidirectional; gut-derived metabolites and toxins affect the progression of CKD, and the uremic milieu affects the microbiota. The accumulation of microbial metabolites and toxins is linked to the loss of kidney functions and increased mortality risk, yet renoprotective metabolites such as short-chain fatty acids and bile acids help restore kidney functions and increase the survival rate in CKD patients. Specific dietary interventions to alter the gut microbiome could improve clinical outcomes in patients with CKD. Low-protein and high-fiber diets increase the abundance of bacteria that produce short-chain fatty acids and anti-inflammatory bacteria. Fluctuations in the urinary microbiome are linked to increased susceptibility to infection and antibiotic resistance. In this review, we describe the potential role of the gut, urinary and blood microbiome in CKD pathophysiology and assess the feasibility of modulating the gut microbiota as a therapeutic tool for treating CKD.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fmed.2021.790783" target="_blank">https://dx.doi.org/10.3389/fmed.2021.790783</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_53a770f1cc24acd3346a7d73090863ac |
| identifier_str_mv | 10.3389/fmed.2021.790783 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25663881 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | The Human Microbiome in Chronic Kidney Disease: A Double-Edged SwordEman Wehedy (13275305)Ibrahim F. Shatat (14150601)Souhaila Al Khodor (89983)Biomedical and clinical sciencesClinical scienceschronic kidney diseasegut microbiotaurinary microbiomedysbiosisuremic toxinsrenoprotectivediet therapy<p dir="ltr">Chronic kidney disease (CKD) is an increasing global health burden. Current treatments for CKD include therapeutics to target factors that contribute to CKD progression, including renin–angiotensin–aldosterone system inhibitors, and drugs to control blood pressure and proteinuria control. Recently, associations between chronic disease processes and the human microbiota and its metabolites have been demonstrated. Dysbiosis—a change in the microbial diversity—has been observed in patients with CKD. The relationship between CKD and dysbiosis is bidirectional; gut-derived metabolites and toxins affect the progression of CKD, and the uremic milieu affects the microbiota. The accumulation of microbial metabolites and toxins is linked to the loss of kidney functions and increased mortality risk, yet renoprotective metabolites such as short-chain fatty acids and bile acids help restore kidney functions and increase the survival rate in CKD patients. Specific dietary interventions to alter the gut microbiome could improve clinical outcomes in patients with CKD. Low-protein and high-fiber diets increase the abundance of bacteria that produce short-chain fatty acids and anti-inflammatory bacteria. Fluctuations in the urinary microbiome are linked to increased susceptibility to infection and antibiotic resistance. In this review, we describe the potential role of the gut, urinary and blood microbiome in CKD pathophysiology and assess the feasibility of modulating the gut microbiota as a therapeutic tool for treating CKD.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fmed.2021.790783" target="_blank">https://dx.doi.org/10.3389/fmed.2021.790783</a></p>2022-01-17T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3389/fmed.2021.790783https://figshare.com/articles/journal_contribution/The_Human_Microbiome_in_Chronic_Kidney_Disease_A_Double-Edged_Sword/25663881CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/256638812022-01-17T03:00:00Z |
| spellingShingle | The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword Eman Wehedy (13275305) Biomedical and clinical sciences Clinical sciences chronic kidney disease gut microbiota urinary microbiome dysbiosis uremic toxins renoprotective diet therapy |
| status_str | publishedVersion |
| title | The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword |
| title_full | The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword |
| title_fullStr | The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword |
| title_full_unstemmed | The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword |
| title_short | The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword |
| title_sort | The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword |
| topic | Biomedical and clinical sciences Clinical sciences chronic kidney disease gut microbiota urinary microbiome dysbiosis uremic toxins renoprotective diet therapy |